Expanded Access Policy

Accutar Biotechnology Inc. (Accutar) is a clinical stage company that harnesses AI to accelerate drug discovery.

Investigational drugs that have not been approved by a regulatory authority, such as the Food and Drug Administration in the United States, may or may not be safe and effective as a treatment option. Clinical trials are designed to evaluate the safety and efficacy of investigational agents. Expanded Access refers to a pathway by which patients who have serious or life-threatening diseases may obtain access to an investigational drug outside the confines of a clinical trial.

At this early stage in our clinical development, Accutar does not offer an Expanded Access Program. We encourage patients to discuss their eligibility for a clinical trial with their treating physician. Information about our ongoing clinical trials, including eligibility criteria and locations, can be found at the following link: clinicaltrials.gov .

We recognize the need for the Expanded Access Program, and we will continue to evaluate our policy based on emerging data from ongoing and future clinical trials. Please contact us at medical@accutarbio.com for any questions you may have regarding our Expanded Access Policy.